106635-86-3

Basic information

• Product Name: 2,6-DIMETHOXY-4-METHYL-5-[3-(TRIFLUOROMETHYL)PHENOXY]QUINOLIN-8-AMINE
• Synonyms: 2,6-DIMETHOXY-4-METHYL-5-[3-(TRIFLUOROMETHYL)PHENOXY]QUINOLIN-8-AMINE;2,6-Dimethoxy-4-methyl-5-[3-(trifluoromethyl)-phenoxy]-8-quinolinamine
• CAS NO: 106635-86-3
• Molecular Formula: C₁₉H₁₇F₃N₂O₃
• Molecular Weight: 378.35
• Mol File: 106635-86-3.mol

Chemical Properties

• Boiling Point: 486.277°C at 760 mmHg
• Flash Point: 247.892°C
• Appearance: /
• Density: 1.316g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.583
• CAS DataBase Reference: 2,6-DIMETHOXY-4-METHYL-5-[3-(TRIFLUOROMETHYL)PHENOXY]QUINOLIN-8-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-DIMETHOXY-4-METHYL-5-[3-(TRIFLUOROMETHYL)PHENOXY]QUINOLIN-8-AMINE(106635-86-3)
• EPA Substance Registry System: 2,6-DIMETHOXY-4-METHYL-5-[3-(TRIFLUOROMETHYL)PHENOXY]QUINOLIN-8-AMINE(106635-86-3)

Safety Data

• Hazardous Substances Data: 106635-86-3(Hazardous Substances Data)

Usage

Uses

Used in Medicinal Chemistry Research:
2,6-DIMETHOXY-4-METHYL-5-[3-(TRIFLUOROMETHYL)PHENOXY]QUINOLIN-8-AMINE is used as a research compound for exploring its pharmacological properties and potential applications in the development of new drugs. Its unique molecular structure and substituents may contribute to specific biological activities, making it a valuable candidate for further investigation in the field of medicinal chemistry.
Used in Pharmaceutical Development:
In the pharmaceutical industry, 2,6-DIMETHOXY-4-METHYL-5-[3-(TRIFLUOROMETHYL)PHENOXY]QUINOLIN-8-AMINE may be utilized as a lead compound for the design and synthesis of novel therapeutic agents. Its potential pharmacological properties could be harnessed to target specific diseases or conditions, subject to further research and optimization of its chemical structure for improved efficacy and safety.

InChI:InChI=1/C19H17F3N2O3/c1-10-7-15(26-3)24-17-13(23)9-14(25-2)18(16(10)17)27-12-6-4-5-11(8-12)19(20,21)22/h4-9H,23H2,1-3H3

Upstream product

• 67-56-1 methanol 
• 106635-85-2 8-amino-2-chloro-6-methoxy-4-methyl-5-<3-(trifluoromethyl)phenoxy>quinoline 
• 82333-41-3 8-amino-6-methoxy-4-methyl-5-(3-trifluoromethylphenoxy)quinoline 
• 106635-82-9 6-methoxy-4-methyl-8-phthalimido-5-<3-(trifluoromethyl)phenoxy>quinoline 
• 106635-84-1 2-chloro-6-methoxy-4-methyl-8-phthalimido-5-<3-(trifluoromethyl)phenoxy>quinoline 
• 106635-83-0 6-methoxy-4-methyl-8-phthalimido-5-<3-(trifluoromethyl)phenoxy>quinoline 1-oxide 
• 189746-15-4 8-nitro-2,6-dimethoxy-5-(3-trifluoromethyl)phenoxy-4-methylquinoline 

Downstream Products

• 106635-87-4 2,6-dimethoxy-4-methyl-8-<(4-phthalimido-1-methylbutyl)amino>-5-<3-(trifluoromethyl)phenoxy>quinoline 
• 106635-80-7 tafenoquine 
• 622405-66-7 8-[(1-methyl-4-nitrobutyl)amino]-2,6-dimethoxy-4-methyl-5-(3-trifluoromethylphenoxy)quinoline 

Relevant articles and documents

Process for the preparation of anti-malarial drugs

The invention relates to novel intermediates and processes for the preparation of quinoline compounds useful as anti-malarial drugs and novel intermediates useful in the process. A process for the preparation of a compound of formula (I) in which R1is C1-6alkyl; R2and R3are independently hydrogen, halogen, trifluoromethyl or C1-6alkoxy; R4is C1-6alkyl; R5is hydrogen or C1-6alkyl; and R6or amino which comprises reacting a compound of formula (II) in which R1, R4and R5are as defined in formula (I) and X is a leading group with a compound of formula (III).

Antimalarials. 16. Synthesis of 2-substituted analogues of 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3- (trifluoromethyl)phenoxy]quinoline as candidate antimalarials

A series of 2-substituted analogues of the exceptional drug 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3- (trifluoromethyl)phenoxy]quinoline (I) were prepared and evaluated for both suppressive and prophylactic antimalarial activity. The preparation of analogues of compound I was of interest due to the high level of both blood and tissue schizonticidal activity demonstrated by this compound. One analogue, 8a, was found to be both more active and less toxic than the parent compound I. In addition, three analogues of example 8a were prepared. Although two of the three analogues showed significant antimalarial activity, both were inferior to compound 8a.